MDT

89.67

-0.33%↓

VEEV

282.32

+2.35%↑

120.08

-2.61%↓

WBA

11.51

0%↓

HQY

97.34

+3.06%↑

MDT

89.67

-0.33%↓

VEEV

282.32

+2.35%↑

120.08

-2.61%↓

WBA

11.51

0%↓

HQY

97.34

+3.06%↑

MDT

89.67

-0.33%↓

VEEV

282.32

+2.35%↑

120.08

-2.61%↓

WBA

11.51

0%↓

HQY

97.34

+3.06%↑

MDT

89.67

-0.33%↓

VEEV

282.32

+2.35%↑

120.08

-2.61%↓

WBA

11.51

0%↓

HQY

97.34

+3.06%↑

MDT

89.67

-0.33%↓

VEEV

282.32

+2.35%↑

120.08

-2.61%↓

WBA

11.51

0%↓

HQY

97.34

+3.06%↑

Kodu・Aktsiate loetelu・Fate Therapeutics Inc

Fate Therapeutics Inc

Suletud

SektorTervishoid

1.14

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.13

Max

1.16

Põhinäitajad
By Trading Economics
Sissetulek	15M -38M
Müük	-231K 1.6M
Kasumimarginaal	-2,309.454
Töötajad	181
EBITDA	4.3M -38M

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	+282.61% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	11. aug 2025

Turustatistika
By TradingEconomics
Turukapital	5.8M 128M
Eelmine avamishind	1.14
Eelmine sulgemishind	1.14

Uudiste sentiment

By Acuity

10%

90%

3 / 376 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

0.9101 / 1.14 Toetus ja vastupanu

Fate Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

14. juuli 2025, 22:07 UTC

Suurimad hinnamuutused turgudel

Trade Desk Rises on S&P 500 Inclusion

14. juuli 2025, 17:06 UTC

Suurimad hinnamuutused turgudel

Crypto Assets Rally Ahead of Possible U.S. Legislation

14. juuli 2025, 16:47 UTC

Omandamised, ülevõtmised, äriostud

NatWest to Sell Stake in Permanent TSB

14. juuli 2025, 23:46 UTC

Market Talk

Nikkei May Rise as Yen Weakens -- Market Talk

14. juuli 2025, 23:38 UTC

Market Talk

Gold Edges Higher Ahead of U.S. CPI Data -- Market Talk

14. juuli 2025, 23:37 UTC

Market Talk

ANZ's Institutional Earnings Likely to Weigh on Outlook -- Market Talk

14. juuli 2025, 23:29 UTC

Market Talk

South32 Bull Eyes Possible Last-Minute Power Deal for Mozal -- Market Talk

14. juuli 2025, 23:29 UTC

Market Talk

Global Energy Roundup: Market Talk

14. juuli 2025, 23:02 UTC

Tulu

China Vanke: Additional Provision for Asset Impairment Also Among Factors Weighing on Results >000002.SZ

14. juuli 2025, 23:02 UTC

Tulu

China Vanke: Weakness in Overall China Real-Estate Sector Weighed on Results >000002.SZ

14. juuli 2025, 23:02 UTC

Tulu

China Vanke 1H Loss Was CNY9.85B >000002.SZ

14. juuli 2025, 23:01 UTC

Tulu

China Vanke Sees 1H Loss CNY10.0B-Loss CNY12.0B >000002.SZ

14. juuli 2025, 23:01 UTC

Tulu

China Vanke Expects 1H Loss to Widen >000002.SZ

14. juuli 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

14. juuli 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

14. juuli 2025, 20:07 UTC

Market Talk

Cloud Computing Giants Will Be the Winner from Software's Loss -- Market Talk

14. juuli 2025, 20:05 UTC

Market Talk

Adobe and Salesforce May Struggle to Keep Up With AI Agents -- Market Talk

14. juuli 2025, 19:11 UTC

Market Talk

Oil Retreats Despite Trump Threats of Russia Sanctions -- Market Talk

14. juuli 2025, 19:09 UTC

Market Talk

Gold Breaks a 3-Day Win Streak -- Market Talk

14. juuli 2025, 18:59 UTC

Market Talk

Hotter Weather Outlook, LNG Flows Boost U.S. Natural Gas -- Market Talk

14. juuli 2025, 18:30 UTC

Omandamised, ülevõtmised, äriostud

Synopsys Buy of Ansys Gets China OK. The $35 Billion Deal Is Set to Close. -- Barrons.com

14. juuli 2025, 18:25 UTC

Market Talk

Dollar Gains, Treasury Yields Lose Steam as Trump Threatens Russia -- Market Talk

14. juuli 2025, 18:25 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

14. juuli 2025, 16:59 UTC

Market Talk

Goldman Sachs Lifts 2H25 Crude Price Views -- Market Talk

14. juuli 2025, 16:53 UTC

Kuumad aktsiad

Stocks to Watch Monday: Kenvue, Tesla, Synopsys, Robinhood -- WSJ

14. juuli 2025, 16:27 UTC

Market Talk

Oil Falls as Investors Monitor U.S.-EU Trade, Trump's Russia Sanction Threats -- Market Talk

14. juuli 2025, 16:20 UTC

Market Talk

Tulu

Auto & Transport Roundup: Market Talk

14. juuli 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

14. juuli 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

14. juuli 2025, 16:12 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Waters Closer to Thermo Fisher, Danaher With Becton Dickinson Unit -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Fate Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

282.61% tõus

12 kuu keskmine prognoos

Keskmine 4.4 USD 282.61%

Kõrge 12 USD

Madal 1 USD

Põhineb 11 Wall Streeti analüütiku instrumendi Fate Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

11 ratings

Osta

Hoia

Müü

Põhineb 11 analüütiku instrumendi Fate Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.9101 / 1.14Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

3 / 376 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.